Bayesian Dose-Finding in Two Treatment Cycles Based on the Joint Utility of Efficacy and Toxicity

REFERENCES

• Albert, J.H., Chib, S. (1993), Bayesian Analysis of Binary and Polychotomous Response Data, Journal of the American Statistical Association, 88, 66–99.
   Web of Science ®Google Scholar
• Almirall, D., Have, T., Murphy, S.A. (2010), Structural Nested Mean Models for Assessing Time-Varying Effect Moderation, Biometrics, 66, 131–139.
   PubMed Web of Science ®Google Scholar
• Ashford, J.R., Sowden, R.R. (1970), Multi-Variate Probit Analysis, Biometrics, 26, 535–546.
   PubMed Web of Science ®Google Scholar
• Azriel, D., Mandel, M., Rinott, Y. (2011), The Treatment Versus Experiment Dilemma in Dose-Finding Studies, Journal of the Statistical Planning and Inference, 141, 2759–2768.
   Web of Science ®Google Scholar
• Bartroff, J., Lai, T.L. (2010), Approximate Dynamic Programming and Its Applications to the Design of Phase I Cancer Trials, Statistical Science, 25, 255–257.
   Web of Science ®Google Scholar
• Bekele, B.N., Ji, Y., Shen, Y., Thall, P.F. (2008), Monitoring Late Onset Toxicities in Phase I Trials Using Predicted Risks, Biostatistics, 9, 442–457.
   PubMed Web of Science ®Google Scholar
• Bekele, B.N., Thall, P.F. (2004), Dose-Finding Based on Multiple Toxicities in a Soft Tissue Sarcoma Trial, Journal of the American Statistical Association, 99, 26–35.
   Web of Science ®Google Scholar
• Bellman, R.E. (1957), Dynamic Programming, Princeton, NJ: Princeton University Press.
   Google Scholar
• Braun, T.M., Kang, S., Taylor, J. M.G. (2012), A Phase I/II Trial Design When Response is Unobserved in Subjects With Dose-Limiting Toxicity, Statistical Methods in Medical Research [online].
   PubMed Web of Science ®Google Scholar
• Braun, T.M., Thall, P.F., Nguyen, H., de Lima, M. (2007), Simultaneously Optimizing Dose and Schedule of a New Cytotoxic Agent, Clinical Trials, 4, 113–124.
   PubMed Web of Science ®Google Scholar
• Braun, T.M., Yuan, Z., Thall, P.F. (2005), Determining a Maximum Tolerated Schedule of a Cytotoxic Agent, Biometrics, 61, 335–343.
   PubMed Web of Science ®Google Scholar
• Cheung, Y.-K. (2011), Dose Finding by the Continual Reassessment Method, London: Chapman & Hall/CRC Biostatistics Series.
   Google Scholar
• Cheung, Y.-K., Chappell, R. (2000), Sequential Designs for Phase I Clinical Trials With Late-Onset Toxicities, Biometrics, 56, 1177–1182.
   PubMed Web of Science ®Google Scholar
• Chevret, S.C. (2006), Statistical Methods for Dose Finding Experiments, Chichester, UK: Wiley.
   Google Scholar
• Chib, S., Greenberg, E. (1998), Analysis of Multivariate Probit Models, Biometrika, 85, 3471.
   Web of Science ®Google Scholar
• Collins, L.M., Murphy, S.A., Nair, V.N., Strecher, V.J. (2005), A Strategy for Optimizing and Evaluating Behavioral Interventions, Annals of Behavioral Medicine, 30, 65–73.
   PubMed Web of Science ®Google Scholar
• de Lima, M., Champlin, R.E., Thall, P.F., Wang, X., Cook, J.D., Martin, T.G., McCormick, G., Qazilbash, M., Kebriaei, P., Couriel, D., Shpall, E.J., Khouri, I., Anderlini, P., Hosing, C., Chan, K.E., Patah, P.A., Caldera, Z., Jabbour, E., Giralt, S. (2008), Phase I/II Study of Gemtuzumab Ozogamicin Added to Fludarabine, Melphalan and Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk CD33 Positive Myeloid Leukemias And Myelodysplastic Syndrome, Leukemia, 22, 258–264.
   PubMed Web of Science ®Google Scholar
• Hernan, M., Brumback, B., Robins, J. (2000), Marginal Structural Models to Estimate the Causal Effect of Zidovudine on the Survival of HIV-Positive Men, Epidemiology, 11, 561–570.
   PubMed Web of Science ®Google Scholar
• Lavori, P.W., Dawson, R. (2001), Dynamic Treatment Regimes: Practical Design Considerations, Statistics in Medicine, 20, 1487–1498.
   PubMed Web of Science ®Google Scholar
• Li, Y., Bekele, B.N., Ji, Y., Cook, J.D. (2008), Dose-Schedule Finding in Phase I/II Clinical Trials Using a Bayesian Isotonic Transformation, Statistics In Medicine, 27, 4895–4913.
   PubMed Web of Science ®Google Scholar
• Lunceford, J., Davidian, M., Tsiatis, A.A. (2002), Estimation of the Survival Distribution of Treatment Policies in Two-Stage Randomization Designs in Clinical Trials, Biometrics, 58, 48–57.
   PubMed Web of Science ®Google Scholar
• Moodie, E. E.M., Richardson, T.S., Stephens, D.A. (2007), Demystifying Optimal Dynamic Treatment Regimes, Biometrics, 63, 447–455.
   PubMed Web of Science ®Google Scholar
• Morita, S., Thall, P.F., Mueller, P. (2010), Evaluating the Impact of Prior Assumptions in Bayesian Biostatistics, Statistics in Biosciences, 2, 1–17.
   PubMedGoogle Scholar
• Murphy, S. (2003), Optimal Dynamic Treatment Regimes ( with discussion), Journal of the Royal Statistical Society, Series B, 65, 331–366.
   Google Scholar
• ——— (2005), A Generalization Error for Q-Learning,” Journal of Machine Learning Research, 6, 1037–1097.
   Web of Science ®Google Scholar
• Murphy, S., Bingham, D. (2009), Screening Experiments for Developing Dynamic Treatment Regimes, Journal of American Statistical Association, 104, 391–408.
   PubMed Web of Science ®Google Scholar
• Murphy, S.A., Collins, L.M., Rush, A.J. (2007), Customizing Treatment to the Patient: Adaptive Treatment Strategies, Drug and Alcohol Dependence, 88, S1–S3.
   PubMed Web of Science ®Google Scholar
• Murphy, S.A., Lynch, K.G., Oslin, D., Mckay, J.R., TenHave, T. (2007), Developing Adaptive Treatment Strategies in Substance Abuse Research, Drug and Alcohol Dependence, 88s, S24–S30.
   Google Scholar
• Murphy, S.A., van der Laan, M.J., Robins, J.M. (2001), Marginal Mean Models for Dynamic Regimes, Journal of the American Statistical Association, 96, 1410–1423.
   PubMed Web of Science ®Google Scholar
• O’Quigley, J., Pepe, M., Fisher, L. (1990), Continual Reassessment Method: A Practical Design for Phase I Clinical Trials in Cancer, Biometrics, 46, 33–48.
   PubMed Web of Science ®Google Scholar
• Robins, J.M. (1986), A New Approach to Causal Inference in Mortality Studies With Sustained Exposure Periods—Application to Control of the Healthy Survivor Effect, Mathematical Modeling, 7, 1393–1512.
   Web of Science ®Google Scholar
• ——— (1993), “Analytic Methods for Estimating HIV Treatment and Cofactor Effects,” in Methodological Issues of AIDS Mental Health Research, eds. D.G. Ostrow and R. Kessler, New York: Plenum Publishing, pp. 213–290.
   Google Scholar
• ——— (1997), Causal Inference from Complex Longitudinal Data Latent Variable Modeling and Applications to Causality, Lecture Notes in Statistics (120), ed. M. Berkane, New York: Springer Verlag, pp. 69–117.
   Google Scholar
• ——— (1998), Marginal Structural Models, Proceedings of the American Statistical Association Section on Bayesian Statistics, 1–10.
   Google Scholar
• Robins, J.M., Hernan, M.A., Brumback, B. (2000), Marginal Structural Models and Causal Inference in Epidemiology, Epidemiology, 11, 550–560.
   PubMed Web of Science ®Google Scholar
• Rush, A.J., Trivedi, M., (2003), Depression IV: STAR*D Treatment Trial For Depression, American Journal of Psychiatry, 160, 237.
   PubMed Web of Science ®Google Scholar
• Spiegelhalter, D.J., Abrams, K.R., and Myles, J. P. (2004), Bayesian Approaches to Clinical Trials and Health-Care Evaluation, Chichester, UK: Wiley.
   Google Scholar
• Sutton, R.S., and Barto, A.G. (1998), Reinforcement Learning: An Introduction, Cambridge, MA: MIT Press.
   Google Scholar
• Thall, P.F., Millikan, R., Sung, H.-G. (2000), Evaluating Multiple Treatment Courses in Clinical Trials, Statistics in Medicine, 19, 1011–1028.
   PubMed Web of Science ®Google Scholar
• Thall, P.F., Nguyen, H.Q. (2012), Adaptive Randomization to Improve Utility-Based Dose-Finding With Bivariate Ordinal Outcomes, Journal of the Biopharmaceutical Statistics, 22, 785–801.
   PubMed Web of Science ®Google Scholar
• Thall, P.F., Nguyen, H.Q., Estey, E.H. (2008), Patient-Specific Dose-Finding Based on Bivariate Outcomes and Covariates, Biometrics, 64, 1126–1136.
   PubMed Web of Science ®Google Scholar
• Thall, P.F., Sung, H.-G., Estey, E.H. (2002), Selecting Therapeutic Strategies Based on Efficacy and Death in Multi-Course Clinical Trials, Journal of the American Statistical Association, 97, 29–39.
   Web of Science ®Google Scholar
• Thall, P.F., Wooten, L.H., Logothetis, C.J., Millikan, R., Tannir, N.M. (2007), Bayesian and Frequentist Two-Stage Treatment Strategies Based on Sequential Failure Times Subject to Interval Censoring, Statistics in Medicine, 26, 4687–4702.
   PubMed Web of Science ®Google Scholar
• Tokic, M. (2010), “Adaptive-Greedy Exploration in Reinforcement Learning Based on Value Differences, ε” in Advances in Artificial Intelligence, Heidelberg, Germany: Springer Verlag, pp. 203–210.
   Google Scholar
• Wahed, A.S., and Tsiatis, A.A. (2006), Semiparametric Estimation of Survival Distribution for Treatment Policies in Two-Stage Randomization Designs in Clinical Trials with Censored Data,” Biometrics, 93, 163–177.
   Web of Science ®Google Scholar
• ——— (2004), Optimal Estimator for the Survival Distribution and Related Quantities for Treatment Policies in Two-Stage Randomization Designs in Clinical Trials, Biometrics, 60, 124–133.
   PubMed Web of Science ®Google Scholar
• Wang, L., Rotnitzky, A., Lin, X., Millikan, R., Thall, P.F. (2012), Evaluation of Viable Dynamic Treatment Regimes in a Sequentially Randomized Trial of Advanced Prostate Cancer with discussion, Journal of American Statistical Association, 107, 493–520.
   PubMed Web of Science ®Google Scholar
• Watkins, C. J. C. H. (1989), “Learning From Delayed Rewards,” unpublished PhD thesis, Cambridge University.
   Google Scholar
• Yin, G. (2012), Clinical Trial Design: Bayesian and Frequentist Adaptive Methods, New York: Wiley.
   Google Scholar
• Yin, G., Li, Y., Ji, Y. (2006), Bayesian Dose-Finding in Phase I/II Clinical Trials Using Toxicity and Efficacy Odds Ratios, Biometrics, 62, 777–789.
   PubMed Web of Science ®Google Scholar
• Zhang, J., Braun, T.M. (2013), A Phase I Bayesian Adaptive Design to Simultaneously Optimize Dose and Schedule Assignments Both Between and Within Patients, Journal of the American Statistical Association, 108, 892–901.
   Web of Science ®Google Scholar
• Zhao, Y., Zheng, D., Socinski, M.A., Kosorok, M.R. (2011), Reinforcement Learning Strategies for Clinical Trials in Nonsmall Cell Lung Cancer, Biometrics, 67, 1422–1433.
   PubMed Web of Science ®Google Scholar
• Zohar, S., Chevret, S. (2007), Recent Developments in Adaptive Designs for Phase I/II Dose-Finding Studies, Journal of Biopharmaceutical Statistics, 17, 1071–1083.
   PubMed Web of Science ®Google Scholar